In a report released yesterday, Charlie CY Yang from Bank of America Securities maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLX – Research Report), with a price target of $10.00.

17:08 EST Recursion Pharmaceuticals (RXRX) files automatic mixed securities shelf Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make ...

EightCAP, Inc., a Community Action Agency dedicated to helping people and changing lives, is excited to announce the launch of its new logo and brand identity. This rebranding initiative reflects ...

Merck & Co. Inc.-1.67% $209.99B ...

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and ...

Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine ...

SEC Filings provided by EDGAR Online, Inc.

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said ...

Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended. J&J resumes ...